Belumosudil, also known as KD-025 and WHO11343, is an orally bioavailable inhibitor of ROCK-II that is greater than 200-fold selective over ROCK-I (IC50s = 105 nM and 24 µM, respectively). Belumosudil (SLx-2119; 40 µM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. Belumosudil (KD025; 100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. It is used in the treatment of Autoimmune Diseases. Belumosudil was approved in 2021 in USA To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy
ROCK Inhibitors Related Products:
Y-27632 dihydrochloride; Y-27632; Fasudil HCl; GSK429286A; RKI-1447; Azaindole-1; AT13148; Thiazovivin